- Aesthetic Medicine
- Aesthetic Surgery
- ALS Treatment
- Brain Injury Treatment
- Cerebral Palsy
- Cerebral Palsy Treatment
- FDA Stem Cell Trials
- Gene Therapy Trials
- Hormone Replacement Therapy
- Mesenchymal Stem Cells
- MS Treatment
- Muscular Dystrophy Treatment
- Parkinson's Treatment
- Retinitis Pigmentosa
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Ulcerative Colitis
Category Archives: Parkinson’s Treatment
Posted: August 15, 2017 at 1:40 pm
Melbourne, Australia and Minneapolis, Minn., Aug. 14, 2017 /PRNewswire/ — Global Kinetics Corporation (GKC), a digital health company revolutionizing the management of Parkinson’s disease, announced today it has recently received Notice of Allowance for U.S. patent application 12/997540, protecting the company’s lead product, the Personal KinetiGraph (PKG) (Parkinson’s Kinetigraph outside of the U.S.) system, which the company is marketing in the U.S. The patent application pertains to the objective measurement of bradykinesia. Bradykinesia, or slowness of movement, is one of the most common symptoms, and a defining feature, of Parkinson’s disease. The capacity to continuously measure this movement symptom underpins the PKG system.
“The allowance of this application supports GKC’s continued progress in the commercialization of our novel, U.S. FDA-cleared PKG system, which is being used to support the management of Parkinson’s disease in over 215 clinics in 16 countries around the world,” said GKC’s global head of business development and legal affairs, Michelle Goldsmith. “We are aggressively pursuing clinical and commercial milestones that will ultimately enable us to make measurable change in the lives of people with Parkinson’s.”
The PKG system, developed by Professor Malcolm Horne and Dr. Rob Griffiths following many years of research at Melbourne’s Howard Florey Institute and Monash University, incorporates a patient-friendly wrist-worn device to record body movements over several days as people go about their daily lives. The PKG system is the only commercially available mobile health technology which provides clinically meaningful measurement of the key symptoms of Parkinson’s using cloud-based proprietary algorithms that measure bradykinesia, dyskinesia, tremor, and the relationships of these to medication timing, sleep and exercise.
Inaccurate assessment of Parkinson’s symptoms may result in patients experiencing uncontrolled symptoms, reducing their quality of life and increasing healthcare costs. By adding the PKG system into a patient’s routine care, treating clinicians now have an effective tool that assists them to augment their clinical assessment with GKC’s proprietary objective data, captured by the PKG watch over seven days.
“GKC has long held the view that measurement is key to optimal management in Parkinson’s. Our algorithms underpin GKC’s ability to provide clinically meaningful and actionable information about Parkinson’s symptoms to clinicians,” explained Professor Horne, GKC’s co-founder and chief scientific officer.
The results of a recent study show the PKG system detected 85% of Parkinson’s patients previously considered “controlled” by their treating physician were, in fact, uncontrolled and experiencing treatable symptoms. The study also showed that without the PKG, one third of the patients that the PKG system detected as having treatable symptoms would have been missed by expert movement disorder specialists (MDS).1 When patients, who were classified as uncontrolled, were treated per their physicians’ recommendations, their outcomes improved, including the subgroup where only the PKG, not the MDS, detected the need for treatment changes.1
GKC is currently conducting studies to establish the value of the PKG system in improving the entire advanced therapy pathway from more efficient referrals to better optimization on therapy. Early evidence suggests the PKG may enhance the DBS pathway, this research is ongoing.2
About Global Kinetics Corporation (GKC) and the Parkinson’s KinetiGraphTM System (PKGTM)
GKC, recognized as a Top 10 Most Innovative Health Company by the Fast Company Awards 2017, is a commercial-stage digital health company revolutionizing the management of Parkinson’s.
The company’s PKG System is a patient-friendly, algorithm-based system that records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisionswith the goal of leading to a higher quality of life for patients.
The PKG System continues to be accepted as a first line clinical system and is the only FDA-cleared and clinically validated digital health technology that can provide continuous and objective measurement of patients’ symptoms in everyday environments. This includes the continuous and objective measure of bradykinesia (or slowness of movement), the most clinically important symptom of Parkinson’s disease.
In addition to increased use in routine clinical care for Parkinson’s disease, Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology to help measure the efficacy of new and advanced therapies, as well as use in clinical trials, telehealth, remote monitoring and other augmented platform opportunities.
For more information, visit: http://www.globalkineticscorporation.com.
SOURCE Global Kinetics Corporation
Posted: August 11, 2017 at 7:41 pm
(RTTNews) – Shares of Adamas Pharmaceuticals Inc. (ADMS) have lost more than 9% of their value year to date while the iShares Nasdaq Biotechnology Index (ETF) (IBB) is up more than 14% during the same period.
Adamas is focused on developing new medicines for chronic neurologic conditions like Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease.
The Company’s lead program is ADS-5102, a high-dose *Amantadine, taken once-daily at bedtime, in development for levodopa-induced dyskinesia (LID) in people with Parkinson’s disease.
*Amantadine is an antiviral medication used to prevent or treat certain influenza infections and is also prescribed to relieve symptoms of Parkinson’s disease. The drug is also effective in relieving fatigue in multiple sclerosis.
Parkinson’s disease is a degenerative disorder of the central nervous system characterized by tremor, or shaking often in a hand or leg, and stiff muscles. It is estimated that over 1.5 million people in the U.S. have Parkinson’s disease. Levodopa remains the gold standard to treat Parkinson’s symptoms.
A common and severe complication of the Levodopa therapy is dyskinesia, which refers to non-purposeful, fragmented or jerky motions. Approximately 200,000 Parkinson’s disease patients suffer from Levodopa-induced dyskinesia, or LID.
Adamas’ drug candidate for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, ADS-5102, is under FDA review – with a decision expected to be announced on August 24, 2017.
In phase III trials, ADS-5102 demonstrated a primary reduction of LID and a secondary reduction in *OFF time in Parkinson’s disease patients, with a manageable safety and tolerability profile. (*OFF time refers to periods of the day when the medication is not working well, causing worsening of the symptoms. (Source: AgingCare.com).)
If approved, ADS-5102 will be the first and only approved medicine for the indication of levodopa-induced dyskinesia in people with Parkinson’s disease.
Another near-term catalyst to watch out for is the top-line data from a phase Ib study of ADS-4101.
ADS-4101 is in development for the treatment of partial onset seizures in patients with epilepsy.
The phase 1b study is evaluating the tolerability and pharmacodynamic profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily Vimpat tablets.
Vimpat received FDA approval for the treatment of partial onset seizures in adults with epilepsy in October 2008.
The company announced positive results from its phase Ia trial of ADS-4101 for the treatment of partial onset seizures in epilepsy in May of this year. The data demonstrated that ADS-4101 is better tolerated in healthy volunteers than equivalent doses of Vimpat.
The top-line data from phase Ib study of ADS-4101 are expected to be announced in the third quarter of 2017.
The Company reported second quarter 2017 financial results on August 8, 2017.
Net loss for the recent second quarter widened to $20.7 million or $0.93 per share from $16.9 million or $0.78 per share in the year-ago quarter.
Adamas has not generated any commercial product revenue. Till date, revenue has been generated primarily from license, milestone, and development revenue pursuant to the Company’s license agreement with Allergan plc (AGN).
In the second quarter of 2017, revenue was down to $2 thousand from $222 thousand generated in the comparable year-ago quarter.
Adamas ended June 30, 2017 with $144.9 million of cash.
Shares of Adamas touched a 52-week intraday high of $19.50 on January 6, 2017. The stock is down over 21% from the yearly high and trades around $15.25.
Will the stock experience a run up in anticipation of the FDA decision date? Will ADS-5102 score the regulatory agency’s stamp of approval? Stay tuned…
Read more here:
Company Spotlight: Adamas Pharma – Markets Insider
Posted: at 7:41 pm
MedicalResearch.com Interview with:Dr Dilan Athauda MRCPSobell Department of Motor Neuroscience and Movement DisordersUCL Institute of Neurology & The National Hospital for Neurology and NeurosurgeryLondon
MedicalResearch.com: What is the background for this study?Response: Exenatide is a synthetic version of a naturally occurring protein exendin-4 that was originally discovered by Dr John Eng in the early 1990s in the saliva of the Gila Monster, a venomous lizard native to the Southwestern United states. He and his team were looking for bio-active peptides in insect and lizard venom that could be useful for people with Type 2 diabetes. They discovered that exendin-4 was extremely similar to a human hormone called Glucagon-like peptide-1 (GLP-1). In humans, GLP-1 is secreted after you eat a meal to stimulate insulin secretion (and inhibit glucagon production) of which the end result is a lowering of blood sugar. Unfortunately human GLP-1 is rapidly broken down by a circulating enzyme called dipeptidyl peptidase IV (DPP-IV) and its effects only last minutes.
Importantly, it was discovered that exendin-4 is naturally resistant to the actions of this enzyme, meaning its effects on blood sugar control lasts much longer in the body. These properties made it very attractive to people trying to treat people with Type 2 diabetes and following many successful randomised controlled trials of patients with Type 2 diabetes in 2005, exenatide was approved for use as a treatment. During this time, work led by Nigel Greigs group at the NIA showed that first evidence that exendin-4 had neuroprotective properties, and could protect neurons from a variety of stresses and could also improve growth and rescue degenerating cells. Over the next few years, various groups used exendin-4 in a variety of animal toxin models of Parkinsons disease and showed that exendin-4 could halt the progression of Parkinsonism and prevent cell death in these models through beneficial effects on inflammation, mitochondrial function and cell survival.
Based on this encouraging pre-clinical data, Professor Foltynie supervised the first small, open-label, human trial of exenatide in patients with Parkinsons disease. The team found that patients treated with exenatide for 1 year (in addition to their usual medication) had less decline in their motor symptoms when assessed without their medication compared to the control group (just on their usual medication) and this advantage over the control group was still present 1 year after stopping the exenatide injections. However, this trial was open-label patients knew they were getting a (potentially beneficial) experimental therapy and so we couldnt exclude the fact that placebo effects were explaining some of the results we saw.
As a result of the potentially beneficial results seen in this small open label trial we carried out a double-blind, placebo controlled trial.
MedicalResearch.com: What are the main findings?Response: We found that after 48 weeks, patients treated with exenatide had a small but statistically significant advantage in their motor severity when assessed after temporarily halting their usual medication and that this advantage persisted 12 weeks after stopping exenatide. Datscan imaging also suggested a reduced rate of decline in the exenatide group. Parkinsons disease progresses slowly, and its important to note that these results, though exciting, were small, and patients did not notice any difference in their quality of life or on their day to day activities over the course of the trial period over their usual medication. We therefore need to conduct a much longer follow up trial with a larger group of patients across multiple centres to try to replicate (or refute) our findings and determine whether this advantage that we have seen accumulates with longer term treatment in order to definitively prove that exenatide alters disease progression.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: The results are encouraging this is the strongest indication we have so far that a drug may be affecting the underlying disease itself rather than masking the symptoms of the disease, however we must be cautious and its too early for us to recommend that everyone with Parkinsons disease should be taking this drug. These results, though exciting, were relatively small, and patients did not notice any difference in their quality of life or on their day to day activities over the course of the trial period over their usual medication. We therefore urgently need to conduct a much longer follow up trial with a larger group of patients across multiple centres to try to replicate (or refute) our findings and determine whether this advantage that we have seen accumulates with longer term treatment in order to definitively prove that exenatide alters disease progression.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: We urgently need to conduct a much longer follow up trial with a larger group of patients across multiple centres to try to replicate (or refute) our findings and determine whether this advantage that we have seen accumulates with longer term treatment in order to definitively prove that exenatide alters disease progression.These results support accumulating evidence that this drug (and class of drugs) should be the subject of further investigation to assess their potential as a future therapy for Parkinsons disease.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial
Athauda, Dilan et al. The Lancet , Volume 0 , Issue 0 ,
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
See the original post:
Diabetes Medication Exenatide Shows Promise In Treating … – MedicalResearch.com (blog)
Posted: at 7:41 pm
Mary Blanton, 74, noticed years ago she was dragging her foot a little bit.
“It just kept on getting worse,” she said.
Three years ago, she was diagnosed with Parkinson’s disease by a Houston doctor.
The neurodegenerative brain disorder progresses slowly in most people and, in her case, affects her gait and balance.
So when her doctor recommended a specific type of therapy called LSVT BIG, she turned to a physical therapist she has trusted for the past 20 years or so.
Mary Drost, 55, was working on a doctorate degree at the University of Texas Medical Branch at the time.
Drost’s professor recommended she become certified in the therapy for her last semester because it complemented her coursework.
When Blanton learned Drost would be able to provide the specialized treatment locally, she was able to breathe a sigh of relief.
Drost said with an aging population, this protocol will become more crucial.
Laura Guse, chief clinical officer of LSVT BIG, said the program should be prescribed early in the course of Parkinson’s disease.
“Don’t wait till you’re falling over or having severe problems with your mobility or speech. Do something now,” she said.
Physical and occupational therapists can be certified to offer the treatment intervention, which was developed from a speech treatment called LSVT LOUD.
Guse said they first started training these therapists in 2007 and have since then trained more than 13,000 globally.
“People with Parkinson’s are not aware of how small and how slow their movements are because there’s a sensory deficit,” she said.
The treatment is more than a general exercise approach because it changes a patient’s brain and motor learning, she said.
“We very systematically address sensory impairment so the person learns how big they have to move to be moving normally,” Guse said.
Last week, during her last visit to Victoria Physical Therapy’s office, Blanton learned just how helpful the treatment was.
Drost said the goal was to work one-on-one four consecutive days a week to retrain her brain to use bigger movements.
“She’s doing great,” Drost said as she timed and took detailed notes during Blanton’s most recent therapy session.
She watched Blanton’s balance and how quickly she was able to get up from a chair and walk.
The final test was a six-minute test to see how many feet she could walk continuously.
Drost walked closely behind as Blanton took off down a hallway, determined to do better than she did four weeks before.
“Keep walking big and fast to the very end,” Drost encouraged Blanton.
And she did.
The first time she did the test, she walked 493 feet within six minutes. This time, she walked 1,381 feet.
“That’s very significant,” Drost said. “We have to attribute it to the intervention.”
Blanton just completed the four-week treatment program and plans to continue the exercises at home with the help of her husband of 57 years, Jeff Blanton.
“He is wonderful,” she said. “He didn’t expect me to be so much better after just one time.”
Traveling to doctor’s appointments in Houston is tough, but even a trip to the store is tiring.
“With Parkinson’s, I have to watch what I do because I get super tired,” she said.
Guse said this treatment gives people hope after they’ve been diagnosed with a devastating disease like Parkinson’s.
“It gives them a chance at empowerment that they can’t get from a pill,” she said.
See the original post here:
Therapy improves mobility for Parkinson’s disease patients – Victoria Advocate
Posted: August 9, 2017 at 3:44 pm
His nonprofit foundation has three main goals: first, find a way to halt progression of Parkinson’s with GBA. Next, identify a regenerative approach to repair the damage it wreaks. And finally, find a way to prevent it altogether.
Accomplishing even just the first would be to do something that’s never been done. Despite years of effort and capital from the Michael J. Fox Foundation for Parkinson’s Research to funding from Google founder Sergey Brin treatments for Parkinson’s disease have remained as elusive as those for other devastating neurodegenerative conditions, like Alzheimer’s.
“It has been extremely challenging, and many clinical trials have failed,” said Dr. Dimitri Krainc, chairman of the department of neurology and director of the Center for Rare Neurological Diseases at Northwestern University Feinberg School of Medicine. “However, we have learned important lessons from these failures.”
The disease was first described two centuries ago, in 1817, by British surgeon James Parkinson. In a document he called “An Essay on the Shaking Palsy,” Parkinson described a condition characterized by “involuntary tremulous motion, with lessened muscular power.”
We know now that Parkinson’s results from loss of brain cells, including those that produce the chemical messenger dopamine, important for coordinating movement. Treatments have been developed to provide symptomatic relief, such as levodopa, which helps replenish the brain’s supply of dopamine, but those have a set of problems of their own. Over time, people gradually need to increase the dose, and the medicines can lead to involuntary movement called dyskinesia.
The bigger problem, though, is that levodopa and other approved agents aren’t neuroprotective, said Krainc, “meaning that they do not prevent neurons from degenerating.”
Recent advancements in genetics provide some hope for better drug targets including, according to Krainc, for the kind of Parkinson’s that Silverstein has, driven by a mutation in GBA.
The GBA gene is responsible for creating a protein known as GCase, or glucocerebrosidase, important for helping clear junk out of cells. And work is underway already: A clinical trial from Sanofi’s Genzyme unit is ongoing, and, in January, drugmaker Allergan bought an exclusive option to acquire a company called Lysosomal Therapeutics, whose lead program also focuses on GBA-associated Parkinson’s. Krainc is a co-founder of Lysosomal Therapeutics and chairs its scientific advisory board.
“There is a real need for disease-modifying treatment,” Allergan CEO Brent Saunders told CNBC.
Silverstein said he hopes the most advanced drugs will be able to help him, but he doesn’t plan on depending on them. After his diagnosis, he sent out a massive call for any work in Parkinson’s with GBA.
“We were just floored with the response,” he said. Hundreds of ideas flowed in “some of them a little bit crazier than others” but about 80 he deemed worth looking at more closely.
Since then, the Silverstein Foundation has made six funding grants to academic labs and private biotech companies, and received a $5 million donation from drugmaker Celgene.
Being a patient as well as a venture capitalist has changed Silverstein’s approach.
“As a venture capitalist, your first boss is your investors, so returns are the first thing that you have to be focused on,” he said.
That can lead to less risk-taking than might lead to bigger advances.
“But when you’re a patient, you come at it from a completely different viewpoint,” Silverstein said. “You’re not interested in incremental change. You’re interested in cures.”
Wednesday, along with OrbiMed and gene therapy biotech RegenXBio, the foundation announced the launch of a new company called Prevail Therapeutics. The founders of rare-disease drug giant Alexion, Leonard Bell and Stephen Squinto, are joining the board.
Posted: at 3:43 pm
Good Samaritan at Vincennes is now offering a new treatment for Parkinsons disease.Physical therapistJoy Uy andoccupational therapistJames Schenk of Good Samaritan are certified providers for this Parkinsons treatment program.
LSVT is a new approach to treatment of Parkinsons disease involving the concept of neuroplasticity, the brains ability to reorganize itself by forming new neural connections throughout life. This approach aims to address the internal aspects of Parkinsons disease symptoms, leading to significant functional movements.
There are two sections of LSVT, BIG and LOUD. LSVT BIG is a standardized treatment protocol, which is customized to the unique goals of each patient including both gross and fine motor skills. LSVT LOUD is customized to the unique communication goals of each person across a range of disease severity and communication impairments.
Over the last 25 years, the National Institutes of Health have been researching and developing LSVT BIG and LOUD to help treat patients with symptoms associated with Parkinsons disease.
Uy says she and Schenk are currently utilizing the LSVT treatment protocol to manage the symptoms of Parkinsons patients in Good Samaritans Rehabilitation Center.
Here is the original post:
Good Samaritan now offers new treatment for Parkinson’s – Terre Haute Tribune Star
Posted: at 3:43 pm
Over the past two decades, medical cannabis has become an alternative treatment option for many medical patients across the globe.
While medical studies in this area are by no means complete, there have been many promising findings both in the medical lab and outside of it, which may be indicators of future treatments that could be based on medical cannabis. A disease called Parkinsons disease has recently moved to the forefront of medical investigation involving medical cannabis treatments.
Parkinsons disease is a neurodegenerative brain disorder that occurs when there is a slow reduction in the amount of dopamine produced in the human brains nerve cells. Dopamine is the brain chemical that allows coordinated and smooth muscle movements in the body.
Because the disease affects a persons movements and begins gradually, and because there is no laboratory test for the disease, it can be difficult to spot early on. Through a thorough examination of a patients medical history and repeated neurological exams, most cases can be diagnosed. Parkinsons disease is not generally diagnosed in younger people; age 60 is the age when it usually begins to affect a patient. For the disease to affect a patient noticeably, 60-80 percent of a patients nerve cells must be affected. Early warning signs of Parkinsons disease include:
While Parkinsons disease is not fatal, complications from it can be, and there is no cure. The goal of treatment is to provide the most high-quality life possible once the disease has been diagnosed.
There are four main stages of Parkinsons disease, all accompanied by their own symptoms. Stage one involves mild symptoms that do not interfere with normal, everyday activities of patients tremor and other movement symptoms occur, but only on one side of the body. Changes in posture, walking, and facial expressions may become apparent to friends or family at this stage.
In stage two, tremors and rigidity may appear on both sides of the body, and walking and posture issues are obvious. Daily tasks may become more difficult or take longer, but the patient should still be self-sufficient. Stage three often includes loss of balance and slower movements, possibly with frequent falls. Independence is still possible, but dressing and eating may become more and more difficult at this stage.
In stage four, symptoms of Parkinsons disease may require help from a walker and help with daily tasks this usually results in a loss of independence. Help from family, a friend, or a nurse that either visits daily or lives with the patient may now be required. In stage five, leg stiffness may prevent the patient from walking, and require 24-hour nursing care. Although most symptoms of Parkinsons disease are commonly associated with physical issues, the following non-motor symptoms are also common, particularly in stage five:
Among the types of medical treatment that have been shown to decrease symptoms of Parkinsons disease are surgery, deep brain stimulation (DBS), and various prescribed medications (most common are carbidopa/levodopa, Sinemet, Azilect, Mirapex, ropinirole, and Requip). In DBS, surgically implanted electrodes in the brain block electrical pulses from nerve cells that cause unwanted movements, stopping tremors and other Parkinsons disease symptoms.
A doctor may use magnetic resonance imaging (MRI) or computed tomography (CT) scans to identify parts of the brain producing unwanted movements prior to surgery. DBS uses surgical insertion of a neurostimulator (similar in size to a stopwatch or heart pacemaker) which delivers to electrical stimulation to targeted brain areas. DBS usually involves the thalamus, subthalamic nucleus, and the globus pallidus. DBS is used only for patients who do not respond to other medications and treatments, and is an invasive procedure. Medical cannabis could help prevent such a procedure, and provide an option that Parkinsons disease patients could use in the privacy of their own homes.
The National Parkinsons Foundation acknowledges the current medical cannabis investigations occurring for Parkinsons disease patients, noting that several anecdotal reports show reduced tremors in Parkinsons patients. Ride with Larry is a three-part documentary involving Larry, a man with severe Parkinsons disease who chose to consume medical cannabis to help with his tremors and other symptoms. Because medical cannabis can interact with neurological cannabinoid receptors (CB1 and CB2), it affects the brain and can calm tremors in some patients.
In general, people with Parkinsons disease have fewer CB1 receptors than people without it; boosting CB1 receptors with medical cannabis seems to alleviate dyskinesia and reduce tremors. The difficulty of conducting medical cannabis trials for Parkinsons disease has been and is still affected by national and international laws regarding the use of medical cannabis, as well as the difficulty of conducting a double-blind, placebo controlled trial with medical cannabis. However, some patients are positive that medical cannabis helps their tremors, and have posted videos of the treatment working on websites such as YouTube. In one pilot study, nabilone (a cannabinoid receptor agonist) significantly reduced dyskinesia in seven patients with Parkinsons disease. Several other studies have shown different results, including tic benefits but no dyskinesia benefits.
A more recent study conducted in Europe has demonstrated that some Parkinsons patients enjoy both pain relief and improved motor function following medical cannabis treatments. Parkinsons disease patients in areas of the world where medical cannabis is legal have the option to discuss this form of treatment with their doctors or healthcare professionals if they are not responding to medications or DBS, but more clinical trials are needed to find reliable results for this treatment.
Posted: at 3:43 pm
NEW YORK: A single dose of a life-extending protein hormone — naturally produced in both kidney and brain — may lead to rapid improvement in cognitive and physical performance, indicating potential for the development of treatments for Parkinson’s and Alzheimer’s disease, a study has shown.
The findings showed that administering hormone klotho like a drug improved cognition, including spatial learning and working memory, as well as the ability to navigate and to learn new tasks — deficiencies which may lead to age-related neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease — in young, ageing or impaired mice with normal or low levels of the hormone.
However, it remains unexplained how the piece of the klotho hormone that was injected into the bodies of the mice caused these effects since there is no evidence that klotho is able to enter the brain from the bloodstream, the researchers said.
“It makes us wonder about the connection between the body and the brain,” said Dena Dubal, Associate Professor at the University of California – San Francisco.
“What we saw with acute klotho administration may be similar to what happens with exercise, which also improves cognition and brain health, although we don’t know how,” she added in the paper published online in the journal Cell Reports.
Further, the beneficial effects in young mice occurred within hours of administering a dose of Klotho and far outlasted the time that klotho remained active in the body.
“It suggests that there is a long-lasting effect of even a single treatment and it probably has to do with the remodeling of synapses, the sites where communication among nerve cells takes place,” Dubal said.
Posted: at 3:43 pm
Image caption Ever since Ben Parkinson was a young boy he had wanted to be a paratrooper and he realised his dream when he joined the 7th Parachute Regiment Royal Horse Artillery
A paratrooper who survived some of the the worst-ever battlefield injuries has asked lawyers to investigate concerns over his care.
Lance Bombardier Ben Parkinson lost both legs and suffered more than 40 injuries in a landmine blast in Afghanistan in 2006.
The 31-year-old from Doncaster and his mother are now calling on his care providers for more help.
NHS England said it was working to arrange reviews of his care.
Lawyers claim his care providers are in breach of the Armed Forces Covenant.
More stories from around Yorkshire
The covenant is a promise that those who serve, or have served, in the armed forces, and their families, are treated fairly.
L/Bombardier Parkinson was two weeks from finishing a tour of Afghanistan when his Land Rover hit a mine. Medical staff did not expect him to survive the explosion.
The former paratrooper’s care is provided by the Ministry of Defence (MoD), NHS England and Doncaster Clinical Commissioning Group (CCG) but his mother, Diane Dernie, said the organisations failed to properly co-ordinate her son’s care.
Their legal representatives also say the 540,000 compensation L/Bombardier Parkinson received is not enough to cover his “ongoing and extensive care requirements”.
Lawyers from Irwin Mitchell have now written to the organisations claiming the MoD has failed in its duty to develop a coherent plan of care for the soldier and that NHS England and the CCG have not met their responsibilities.
Mrs Dernie said: “Considering everything that Ben has been through, it was a huge relief to secure some compensation a few years ago and we believed that Ben’s care needs would be met going forward.
“Sadly we have faced a number of issues with support and it has been difficult to identify who is responsible for what parts of Ben’s care.
“Time and again we have asked for these urgent issues to be addressed, but Ben is still not receiving anywhere near the level of funding required to buy all the care he requires.”
The organisations involved with providing care for L/Bombardier Parkinson said they are working together.
An MoD spokeswoman said: “We are developing a new initiative with the NHS to provide patient-centred support.”
A spokeswoman for NHS England said: “We are working with the organisations involved to arrange appropriate reviews of Ben’s ongoing care and treatment requirements.”
A Doncaster CCG spokeswoman confirmed they had received the letter and were acting upon the information.
View original post here:
Injured soldier Ben Parkinson launches review of his care – BBC News
Posted: August 8, 2017 at 1:40 pm
Exenatide, a commonly prescribed drug for type 2 diabetes, could possibly be repurposed as a modifying therapy for patients diagnosed with Parkinsons disease.
Injections of exenatide showed signs of improving movement in Parkinsons patients over a one year period versus those who took placebo, suggested a new study.
Researchers at the University College London followed 60 people with Parkinsons disease as they self-injected either exenatide or a placebo once a week for 48 weeks in addition to regular medications.
Results indicated the patients who performed the exenatide injections exhibited better motor function at 48 weeks when they came off the treatment. This effect persisted after the 12-week follow up.
By contrast, the group who injected the placebo showed a decline in their motor scores at both the 48-week and 60-week tests, according to the announcement.
Overall, the control group had an advantage of four points on a 132 point scale of measures like tremors and agility, which was deemed statistically significant.
Exenatides mechanism of action is that it activates receptors for the GLP-1 hormone in the pancreas in order to stimulate insulin release. These receptors can also be found in the brain where prior research has shown that activating them can boost function of dopamine connections, engage cell survival signals and serve as an anti-inflammatory.
Using approved therapies for one condition to treat another, or drug repurposing, offers new avenues to speed Parkinsons therapeutic development, said Brian Fiske, senior vice president of research programs at the Michael J. Fox Foundation, the primary funder of this study. The results from the exenatide studies justify continued testing, but clinicians and patients are urged not to add exenatide to their regimens until more is known about their safety and impact on Parkinsons.
Previous experiments in animal models illustrated the drugs ability to improve motor performance, but the scientists running this analysis noted the research did not conclusively determine whether drug was actually modifying the disease itself.
The next phase of this research will involve a longer-term study with more participants to ascertain if there are prominent improvements in quality of life.
These findings were published in the journal The Lancet.